CD274 and melanoma: In our laboratory, the subcutaneous immunization with shRNA-SOCS1-transduced viable B16F10-Nex2 tumor cells, which inhibited the expression of PD-L1 rendered significant protection against melanoma in the syngeneic model used (65).